(4-Pack) TESAMORELIN – 10mg
Related Products
Peer-Reviewed Literature
Related Studies
Peer-Reviewed Literature
Related Studies
Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV
New England Journal of Medicine
412 HIV patients receiving tesamorelin 2 mg daily showed selective 18% visceral fat reduction with improved body image over 26 weeks in this landmark NEJM trial.
Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients: A Randomized Clinical Trial
JAMA
Tesamorelin-treated group showed VAT decrease of 27.8 cm² versus 5.1 cm² increase in placebo, with triglyceride reductions of 50 mg/dL and modest hepatic fat improvements.
Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial
The Lancet HIV
61 HIV patients with NAFLD showed absolute hepatic fat reduction of 4.1% (37% relative) versus placebo over 12 months, with evidence of reduced fibrosis progression.
Tesamorelin Reduces Carotid Intima-Media Thickness in HIV-Infected Patients with Excess Abdominal Fat
Journal of Clinical Endocrinology & Metabolism
Tesamorelin treatment for 12 months reduced carotid intima-media thickness (cIMT) in HIV patients, suggesting cardiovascular protective effects beyond its established visceral fat reduction benefits.
Effect of Growth Hormone-Releasing Hormone on Cognitive Function in Adults with Mild Cognitive Impairment and Healthy Older Adults
Archives of Neurology
Twenty-week GHRH (tesamorelin) treatment improved cognitive function, executive function, and verbal memory in both MCI patients and healthy older adults, with enhanced insulin sensitivity and favorable body composition changes.
Tesamorelin Prevents Onset of Hepatic Steatosis in HIV-Infected Individuals
Clinical Infectious Diseases
Post-hoc analysis of 585 HIV patients showed tesamorelin not only reduced existing liver fat but prevented new-onset hepatic steatosis, with number needed to treat of 7 over 12 months.